Bile Acids and Blood Pressure Control
Official title: Conjugated bile acids as nutritionally re-programmable antihypertensive metabolites
Funded at University of Toledo Health Sci Campus · NIH-11139613 · Data updated 2026-11-12
This project explores how certain bile acids, influenced by gut bacteria, might help manage high blood pressure.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Toledo Health Sci Campus NIH-funded |
| Lab location | 1 site (Toledo, United States) |
| Project start | July 16, 2024 |
| Project end | May 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $761,554 |
| NIH project number | 5R01HL171401-02 |
| Project ID | NIH-11139613 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with high blood pressure, particularly those interested in how gut health and metabolism influence their condition, may find this research relevant.
✕Less likely to help
Patients whose high blood pressure is solely due to factors unrelated to gut microbiota or bile acid metabolism may not directly benefit from this specific approach.
What this research studies
High blood pressure is a major cause of heart disease and stroke, with genetics and salt intake being well-known factors. Recent discoveries suggest a novel link between the composition of gut bacteria and high blood pressure. This work focuses on conjugated bile acids, which appear to be significantly lower in individuals with high blood pressure. We aim to understand why these beneficial bile acids are depleted and how restoring them could help improve blood pressure.
Why it matters
Potential benefit: If successful, this work could lead to new strategies for preventing or treating high blood pressure by targeting gut bacteria or bile acid levels, potentially through dietary changes.
How similar studies have gone: This research builds upon recent findings that have identified a connection between gut microbiota composition and high blood pressure, suggesting a novel pathway for intervention.
Where this research is happening
-
University of Toledo Health Sci Campus
Toledo, United States Active
Researchers
- Principal investigator: Joe, Bina — University of Toledo Health Sci Campus
- Study coordinator: Joe, Bina
Related research
Other NIH-funded projects on the same topics.
-
Understanding how ultra-potent opioids harm and how to reverse effects beyond traditional antidotes
Researchers are studying why some extremely strong synthetic opioids cause life-threatening effects and how to counter them, including situations where standard antidotes don’t work well.
-
Platform to Target and Degrade Disease-Causing Proteins
A new approach uses smart molecules to degrade harmful proteins that traditional drugs can’t touch, potentially benefiting people with diseases linked to those proteins.
-
Mitochondrial DNA and inflammation in back disc degeneration
A study to understand how damaged mitochondrial DNA may trigger inflammation and contribute to disc degeneration in adults.
-
Lyme disease vaccine research aimed at preventing infection
Researchers are developing a Lyme disease vaccine by studying how the immune system responds to Borrelia burgdorferi and testing vaccine approaches to prevent illness.
-
Dissecting how TNBC tumors suppress the immune system using myeloid cells
This NIH grant explores how a protein called TAZ helps triple-negative breast cancer evade the immune system, with the goal of improving treatments for patients with this aggressive cancer.
-
Exosome-based delivery to target pancreatic cancer cells
A patient-friendly look at a project that aims to use tiny natural vesicles to carry cancer-fighting therapies directly to pancreatic tumors.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.